Genethon Using AI to Improve Effectiveness of Gene Therapies and Patient Access CEO Frederic Revah discusses how Artificial Intelligence is creating next-generation gene therapy vectors and reducing bioproduction costs in the latest issue of Genethon’s Newsletter Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy…..
MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies
MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies • Major milestone achieved with new state-of-the-art microbiome facility spanning over 1600 m², completed within the 12-month timeframe, further enhancing bioproduction capabilities and contributing to the ecosystem in France and Europe. • MaaT Pharma is…..
Carroucell has raised €1.5 million Carroucell, a French microcarrier supplier for cell culture in bioreactor, has raised a total of €1.5 million. The funding includes the closing of a Series A financing, led by the Novalis Biotech Acceleration fund and with participation of Crédit Agricole des Savoie (CADS), as well…..
New solution for stem cell manufacturing Researchers have developed a unique 3D printed system for harvesting stem cells from bioreactors, offering the potential for high quality, wide-scale production of stem cells in Australia at a lower cost. [caption id="attachment_10614" align="aligncenter" width="700"] Modular 3D printed microfluidic system©Majid Warkiani et al. Bioresources…..
Novartis expands Zolgensma® manufacturing capacity with approval of multi-product North Carolina facility
Novartis expands Zolgensma® manufacturing capacity with approval of multi-product North Carolina facility The FDA has granted commercial licensure approval for Novartis' Durham, N.C. site, a multi-product gene therapy manufacturing facility. This approval allows the state-of-the-art, 170,000 square-foot facility to make, test and release commercial Zolgensma®, as well as produce…..
Touchlight and Versameb announce GMP manufacturing supply agreement to support the development of novel mRNA-based therapeutics
Touchlight and Versameb announce GMP manufacturing supply agreement to support the development of novel mRNA-based therapeutics Touchlight, a UK biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, has concluded a development and manufacturing pipeline agreement with Versameb, a Swiss pre-clinical stage company focused on discovering and…..
MaaT Pharma and SkyePharma to establish the first microbiome-based therapeutics manufacturing facility in France
MaaT Pharma and SkyePharma to establish the first microbiome-based therapeutics manufacturing facility in France MaaT Pharma and Skyepharma have entered a partnership agreement to build SkyeHub Bioproduction, a new manufacturing facility near Lyon. This new plant will be France’s largest specialized cGMP manufacturing facility for ecosystem microbiome-based therapeutics. SkyeHub Bioproduction…..
« L’innovation en bioproduction n’est pas un champ aride en France » Le Grand Défi « Biomédicaments : améliorer les rendements et maîtriser les coûts de production » a maintenant sélectionné 10 projets retenus dans le cadre de ses premiers appels à projets. Alors qu’une nouvelle vague de lauréats va être annoncée prochainement,…..
Les intégrateurs industriels, futurs piliers de la filière Bioproduction ? La France s’est fixée pour objectif de devenir le leader européen de la bioproduction d’ici 2030. Emmanuel Dequier, directeur du Grand Défi « Biomédicaments : améliorer les rendements et maîtriser les coûts de production » nous décline les grands axes des travaux engagés par…..
Celonic will manufacture over 100 million doses of Curevac's COVID-19 Vaccine Candidate, CVnCoV CureVac and Celonic Group have conclud a partnership for the production of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV. CureVac began development of mRNA-based COVID-19 vaccine candidates in January 2020 and CVnCoV is the vaccine candidate chosen for…..